Inzomelid completes Phase I studies and shows positive results in the treatment of Cryopyrin-Associated Periodic Syndrome (CAPS)
Inflazome, the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, today announces the successful completion of a Phase I study of Inzomelid, alongside positive results from a Cryopyrin-Associated Periodic Syndrome (CAPS) patient dosed with Inzomelid. CAPS is an autoinflammatory orphan disease driven by mutated NLRP3. The results support the progression of Inzomelid into Phase II clinical trials.
Dr Jeremy Skillington | VP Business Development
Ireland & International | Jonathan Neilan/Patrick Berkery
If you are a member of the media and have a media query please contact: